SWKHL

SWK Holdings Corp

Add to Watchlist

Advanced Chart

25.515

-0.065(-0.254%)1D

Line

Candle

YTD

High

25.515

Open

25.420

VWAP

25.47

Vol

931.00

Mkt Cap

Low

25.420

Amount

23.71K

EV/EBITDA(TTM)

13.60

Total Shares

12.25M

267.22M

EV/OCF(TTM)

11.59

P/S(TTM)

5.32

SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.

0 Analyst Rating

Wall Street analysts forecast SWKHL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SWKHL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 25.515

Low

Averages

High

Current: 25.515

Low

Averages

High

The End

No Data

Valuation Metrics

The current forward P/E ratio for SWK Holdings Corp (SWKHL.O) is , compared to its 5-year average forward P/E of . For a more detailed relative valuation and DCF analysis to assess SWK Holdings Corp 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS